Alan William Baird

Alan William Baird

Auto-generated profile, based on publicly available information

Alan William Baird

University College Dublin, Belfield, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

49Years (1978-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2000 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
EGElisabet Gullberg
Elisabet Gullberg
MLMaurice Leonard
Maurice Leonard
JKJohan Karlsson
Johan Karlsson
Ann M. HopkinsAnn M. Hopkins
Ann M. Hopkins
David BraydenDavid Brayden
David Brayden
PAPer Artursson
Per Artursson

1 September 2005 in Drug Discovery Today
Verified
Journal Article
Closed access
David BraydenDavid Brayden
David Brayden
MJMark A. Jepson
Mark A. Jepson
ABAlan W. Baird
Alan W. Baird

29 July 2009 in Seminars in Immunopathology
Verified
Journal Article
Closed access
PDF file
ENEszter Nemeth
Eszter Nemeth
ABAlan W. Baird
Alan W. Baird
COCliona O'Farrelly
Cliona O'Farrelly

14 June 2012 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
HMHelen M. Mohan
Helen M. Mohan
CACarol Aherne
Carol Aherne
ARAilin Rogers
Ailin Rogers
ABAlan W. Baird
Alan W. Baird
DWDes C. Winter
Des C. Winter
EMEvelyn P. Murphy
Evelyn P. Murphy
Nuclear receptors are of integral importance in carcinogenesis. Manipulation of classic ligand-activated nuclear receptors, such as estrogen receptor blockade in breast cancer, is an important established cancer therapy. Orphan nuclear receptors, such as nuclear family 4 subgroup A (NR4A) receptors, have no known natural ligand(s). These elusive receptors are increasingly recognized as molecular switches in cell survival and a molecular link between inflammation and cancer. NR4A receptors act as transcription factors, altering expression of downstream genes in apoptosis (Fas-ligand, TRAIL), proliferation, DNA repair, metabolism, cell migration, inflammation (interleukin-8), and angiogenesis (VEGF). NR4A receptors are modulated by multiple cell-signaling pathways, including protein kinase A/CREB, NF-κB, phosphoinositide 3-kinase/AKT, c-jun-NH2-kinase, Wnt, and mitogen-activated protein kinase pathways. NR4A receptor effects are context and tissue specific, influenced by their levels of expression, posttranslational modification, and interaction with other transcription factors (RXR, PPAR-ϒ). The subcellular location of NR4A “nuclear receptors” is also important functionally; novel roles have been described in the cytoplasm where NR4A proteins act both indirectly and directly on the mitochondria to promote apoptosis via Bcl-2. NR4A receptors are implicated in a wide variety of malignancies, including breast, lung, colon, bladder, and prostate cancer; glioblastoma multiforme; sarcoma; and acute and/or chronic myeloid leukemia. NR4A receptors modulate response to conventional chemotherapy and represent an exciting frontier for chemotherapeutic intervention, as novel agents targeting NR4A receptors have now been developed. This review provides a concise clinical overview of current knowledge of NR4A signaling in cancer and the potential for therapeutic manipulation. Clin Cancer Res; 18(12); 3223–8. ©2012 AACR.

1 February 1999 in Gut
Verified
Journal Article
Open access
PDF file
DMD M McKAY
D M McKAY
ABA W Baird
A W Baird

1 October 2001 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
GMG. McCormack
G. McCormack
DMD. Moriarty
D. Moriarty
DOD. P. O'DOnoghue
D. P. O'DOnoghue
PMP. A. McCormick
P. A. McCormick
KSK. Sheahan
K. Sheahan
ABA. W. Baird
A. W. Baird